CVR number 41362731
Industry 21.1000 Manufacture of basic pharmaceutical products

ViruBac ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 19.6% 14.4% 22.9%  
Credit score (0-100)  0 0 6 14 3  
Credit rating  N/A N/A C B C  
Credit limit (kDKK)  0.0 0.0 -0.0 -0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -89.3 -18.9 -14.8  
EBITDA  0.0 0.0 -89.3 -18.9 -14.8  
EBIT  0.0 0.0 -89.3 -18.9 -14.8  
Pre-tax profit (PTP)  0.0 0.0 -91.2 -24.0 77.1  
Net earnings  0.0 0.0 -91.2 -24.0 77.1  
Pre-tax profit without non-rec. items  0.0 0.0 -91.2 -24.0 77.1  
 
See the entire income statement

Balance sheet (kDKK) 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 -51.2 -75.2 1.9  
Interest-bearing liabilities  0.0 0.0 63.6 141 24.1  
Balance sheet total (assets)  0.0 0.0 17.2 87.4 66.7  
Net Debt  0.0 0.0 63.6 78.6 -42.5  
 
See the entire balance sheet

Volume 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -89.3 -18.9 -14.8  
Gross profit growth  0.0% 0.0% 0.0% 78.8% 21.8%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 17 87 67  
Balance sheet change%  0.0% 0.0% 0.0% 408.6% -23.7%  
Added value  0.0 0.0 -89.3 -18.9 -14.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 -2.0 -3.0  

Profitability 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -130.6% -16.4% 68.1%  
ROI %  0.0% 0.0% -140.4% -18.5% 93.4%  
ROE %  0.0% 0.0% -530.9% -45.9% 172.8%  

Solidity 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Equity ratio %  0.0% 0.0% -74.9% -46.3% 2.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -71.2% -415.4% 287.3%  
Gearing %  0.0% 0.0% -124.2% -187.6% 1,274.6%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 5.9% 5.0% 1.1%  

Liquidity 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Quick Ratio  0.0 0.0 0.3 0.5 1.0  
Current Ratio  0.0 0.0 0.3 0.5 1.0  
Cash and cash equivalent  0.0 0.0 0.0 62.6 66.7  

Capital use efficiency 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 -51.2 -75.2 1.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
N/A
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0